India's Richest People 2026 edition · 1 director · Source: Hurun India
- #223 K Satish Reddy & family ₹16,700 Cr
Revenue · FY 2025
₹171.93 Cr
▼ 57% YoY
Net loss · FY 2025
₹81.49 Cr
Net margin -47.4%
EBITDA · FY 2025
-₹80.14 Cr
EBITDA margin -46.6%
Authorised capital
₹240 Cr
Registered with MCA
Paid-up capital
₹187.56 Cr
Issued & subscribed
Satisfied charges
₹6.59 Cr
No open charges
Company age
25 yrs
Est. 2001
Employees · EPFO
479
Provident fund records
About Aurigene Oncology Limited
Data last updated:
Aurigene Oncology Limited is a public limited company based in Bangalore, Karnataka, India, a subsidiary of Dr.Reddy's Laboratories Ltd. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 10 August 2001 and has been in existence for over 25 years.
Its director K Satish Reddy and family are #223 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24239KA2001PLC029391. Its GSTIN is 29AADCA2387A1ZX (Karnataka). The company holds 3 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹240 Cr and a paid-up capital of ₹187.56 Cr. It was formerly known as Aurigene Discovery Technologies P Limited. It is led by directors including Bruce Leonard Andrews Carter and Venkata Ramana Motupalli.
Its last annual general meeting (AGM) was held on 26 July 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 39/49(P)KIADB Industrial Area Electronics City Phase II, Bangalore, Karnataka, India – 560100.
As per the financials filed for FY 2025, the company reported a revenue of ₹171.93 Cr, a decline of 57% compared to the previous year. For the same year it recorded a net loss of ₹81.49 Cr (net margin -47.4%) and EBITDA of -₹80.14 Cr (EBITDA margin -46.6%). Revenue has declined at a compounded annual rate (CAGR) of 18% over three years and 10% over five years.
The company has about 479 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Aurigene. As per MCA filings, the company has satisfied charges of ₹6.59 Cr on record. Court records list 5 cases involving the company, including 3 filed by the company and 2 filed against it; 3 cases are pending. The company has 3 deals on record (2 secondary share transfers, 1 funding round), with disclosed funding of ₹14.75 Cr; the latest was in March 2014. The company has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 34 overdue payments to 8 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aurigene.com.
Company details
CIN U24239KA2001PLC029391
Registration Number 029391
Incorporation Date 10 August 2001
ROC Bangalore
Listing Status Unlisted
Company Status Active
Date of Last AGM 26 July 2024
Date of Balance Sheet 31 March 2024
Parent Company Dr.Reddy's Laboratories Ltd
Compliance Status Active Compliant
CIN history
Aurigene Oncology has one previous CIN (Corporate Identification Number): U24239KA2001PTC029391. The current CIN is U24239KA2001PLC029391, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239KA2001PLC029391 | Current |
| U24239KA2001PTC029391 | Previous |
Key People
Muralidhara Ramachandra Ceo Bruce Leonard Andrews Carter Director Venkata Ramana Motupalli Director Recognitions & Rankings of Aurigene Oncology
Contact details
Aurigene Oncology Limited's registered office is in Bangalore, Karnataka. Its website is aurigene.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address39/49(P)KIADB Industrial Area Electronics City Phase II, Bangalore, Karnataka, India – 560100
- IndustryLife Sciences, Biotechnology
To see the full contact details of Aurigene Oncology Limited, buy the company report.
Comprehensive company report
Aurigene Oncology Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Aurigene Oncology operates one associated brand: Aurigene. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Discovers and develops novel oncology therapeutics via research collaborations. | aurigene.com |
Business activity
The main business activity of Aurigene Oncology is professional, scientific and technical. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Aurigene Oncology Limited, buy the company report.
Financials of Aurigene Oncology Limited
FY 2024 filings availableAurigene Oncology Limited reported revenue of ₹171.93 Cr (down 57% YoY) for FY 2025.
Revenue · FY 2025
₹171.93 Cr ▼ 57%
Net loss · FY 2025
₹81.49 Cr margin -47.4%
EBITDA · FY 2025
-₹80.14 Cr margin -46.6%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 57%
3 years · compounded
▼ 18%
5 years · compounded
▼ 10%
EBITDA CAGR growth
1 year
▼ 168%
3 years · compounded
▼ 41%
5 years · compounded
▼ 21%
Revenue has declined at a compounded annual rate (CAGR) of 10% over five years, including a 57% fall in the latest year. EBITDA fell 168% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹80.14 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹81.49 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -46.6% | ||||
| Net Profit Margin | -47.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Aurigene Oncology Limited, buy the company report.
Board of directors and KMP of Aurigene Oncology Limited
Aurigene Oncology Limited currently reports 7 directors and 1 key managerial person. 25 former directors have served the organization.
Current Directors and KMP
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bruce Leonard Andrews Carter | Director | 30 Mar 2015 | 11 Years 6 Months | Current |
| Venkata Ramana Motupalli | Director | 19 Oct 2023 | 3 Years 0 Months | Current |
| Satish Reddy Kallam Also directs: Dr.Reddy's Laboratories Ltd, Greenpark Hotels and Resorts Limited, Stamlo Industries Limited and 5 more | Director | 10 Aug 2001 | 25 Years 2 Months | Current |
| Kumar Srinivasan | Director | 01 Oct 2022 | 4 Years 0 Months | Current |
| Shubhada Vivek Chiplunkar | Director | 01 Oct 2022 | 4 Years 0 Months | Current |
| Muralidhara Ramachandra Also directs: Dr.Reddy's Institute of Life Sciences | Ceo | 01 Jul 2019 | 7 Years 3 Months | Current |
Showing 6 of 8 current directors and KMP. View all directors and KMP
Auditor
Aurigene Oncology Limited is audited by S.R. Batliboi & Associates LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S.R. Batliboi & Associates LLP | FY 2023 | 101049W/E300004 |
Shareholding
The shareholding of Aurigene Oncology Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Aurigene Oncology Limited, buy the company report.
Charges & borrowings
Open charges
None
Satisfied charges
₹6.59 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 14 Sep 2011 | 10309819 | State Bank of India | ₹6.5 Cr | Satisfied | |
| 21 Oct 2005 | 10309982 | Icici Bank Limited | ₹8.75 Lakh | Satisfied |
To see the full charge records of Aurigene Oncology Limited, buy the company report.
Total charge records: 2 View all charges
Deals & funding
Aurigene Oncology Limited has 3 deals on record (2 secondary share transfers, 1 funding round), with disclosed funding of ₹14.75 Cr; the latest was in March 2014.
Total deals
3
Secondary share transfers
2
Funding round
1
Disclosed funding
₹14.75 Cr
Deals on record (2 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2014 | Secondary share transfer | Undisclosed | Seller: Dr.Reddy's Laboratories Ltd |
| Oct 2009 | Secondary share transfer | Undisclosed | Buyer: Dr.Reddy's Laboratories Ltd Seller: 4 individuals |
To see the full deal history of Aurigene Oncology Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Aurigene Oncology Limited has 5 court cases on record: 3 filed by Aurigene Oncology, 2 filed against it. 3 cases are pending and 2 are disposed.
Total cases
5
Filed by the company
3
Filed against the company
2
Pending
3
Disposed
2
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 5 | 2 | 3 |
Cases on record (2 of 5)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court | Writ petition | Filed by the company against The Union of India and 3 others | Pending |
| High Court of Karnataka | Tax appeal | Filed against the company by The PR Commissioner of Income Tax | Disposed |
To see the full case history of Aurigene Oncology Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Aurigene Oncology Limited was last rated by Icra on 30 May 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 30 May 2022 |
To see the full credit ratings and regulatory alerts of Aurigene Oncology Limited, buy the company report.
MSME payment delays
Aurigene Oncology Limited has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 34 overdue payments to 8 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 8)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Polar Biosciences Private Limited | |||
| an individual supplier | |||
| an individual supplier | |||
| Equitron Medica Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Aurigene Oncology Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Aurigene Oncology has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
1
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Aurigene Pharmaceutical Services Limited | U74999KA2019PLC127964 |
To see the full group structure of Aurigene Oncology Limited, buy the company report.
Employees & EPFO
Aurigene Oncology Limited has a workforce of 479 employees on its EPFO records as of Apr 06, 2024, across 1 active EPFO establishment.
Employee count
479
Active EPFO establishments
1
Employee growth
15.42%
GST
Aurigene Oncology has 3 GST registrations: 2 active and 1 cancelled or inactive.
Total GSTINs
3
Active
2
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AADCA2387A1ZX | Karnataka | Active | 01 Jul 2017 |
| 36AADCA2387A1Z2 | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Aurigene Oncology Limited, buy the company report.
Recent activity
Aurigene Oncology Limited has 27 board changes on record since 2001: 8 appointments and 19 cessations. The latest: Venkata Ramana Motupalli ceased to be Additional Director on 25 Jul 2024.
AGM
Aurigene Oncology Limited last Annual general meeting of members was held on 26 Jul 2024 as per latest MCA records.
Ceased
Venkata Ramana Motupalli ceased to be Additional Director.
Filing
Aurigene Oncology Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Bangalore.
Appointed
Venkata Ramana Motupalli was appointed as Director.
Ceased
Kumar Srinivasan ceased to be Additional Director.
Ceased
Shubhada Vivek Chiplunkar ceased to be Additional Director.
Appointed
Kumar Srinivasan was appointed as Director.
Appointed
Shubhada Vivek Chiplunkar was appointed as Director.
Ceased
Parag Agarwal ceased to be Additional Director.
Ceased
Patrick Aghanian Rudolf ceased to be Additional Director.
Ceased
Saumen Chakraborty ceased to be Director.
Ceased
Venkateswara Prasad Gunupati ceased to be Director.
22 earlier events are in the company report.
News
Frequently asked questions
Aurigene Oncology is an active public limited company based in Bangalore, Karnataka, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 10 August 2001 (25+ years old) and is registered under CIN U24239KA2001PLC029391.
Aurigene Oncology has 8 current directors and KMP:
- Bruce Leonard Andrews Carter - Director
- Venkata Ramana Motupalli - Director
- Satish Reddy Kallam - Director
- Kumar Srinivasan - Director
- Shubhada Vivek Chiplunkar - Director
- Venkateswara Prasad Gunupati - Director
- Buggana Hariharnath - Director
- Muralidhara Ramachandra - Ceo
The latest financial statements of Aurigene Oncology on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 26 July 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Aurigene Oncology is 29AADCA2387A1ZX, registered in Karnataka. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 36AADCA2387A1Z2 (Telangana).
The CIN (Corporate Identification Number) of Aurigene Oncology is U24239KA2001PLC029391. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Aurigene Oncology has 5 court cases on record: 3 filed by the company and 2 filed against it. 3 are pending.
Aurigene Oncology was incorporated on 10 August 2001, making it 25+ years old. It is registered with the Registrar of Companies, Bangalore.
Aurigene Oncology has 3 deals on record (2 secondary share transfers, 1 funding round), with disclosed funding of ₹14.75 Cr; the latest was in March 2014.
Venkata Ramana Motupalli ceased to be Additional Director on 25 Jul 2024. Venkata Ramana Motupalli was appointed as Director on 19 Oct 2023. Kumar Srinivasan ceased to be Additional Director on 13 Oct 2022. Aurigene Oncology has 27 board changes on record in total.
Aurigene Oncology has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 34 overdue payments to 8 micro and small suppliers. The latest return was filed on 30 Apr 2024.
Aurigene Oncology can be reached through the website aurigene.com. Its registered office is in Bangalore, Karnataka, India.